Therapeutic applications of CpG-containing oligodeoxynucleotides.
Klinman
D M
DM
Section of Retroviral Immunology, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000941:Antigens / Q000276:immunology*; D001428:Bacterial Vaccines / Q000276:immunology; D018899:CpG Islands; D016207:Cytokines / Q000096:biosynthesis* / Q000235:genetics; D004341:Drug Evaluation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D007114:Immunization; D008088:Listeriosis / Q000276:immunology / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D009838:Oligodeoxyribonucleotides / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D010047:Ovalbumin / Q000276:immunology; D012481:Salmonella Infections, Animal / Q000276:immunology / Q000517:prevention & control; D012486:Salmonella typhimurium; D014406:Tularemia / Q000276:immunology / Q000517:prevention & control; D019444:Vaccines, DNA / Q000276:immunology*
D000276:Adjuvants, Immunologic; D000941:Antigens; D001428:Bacterial Vaccines; D016207:Cytokines; D009838:Oligodeoxyribonucleotides; D019444:Vaccines, DNA; D010047:Ovalbumin